Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes
- PMID: 18089692
- PMCID: PMC2266957
- DOI: 10.1210/jc.2007-2176
Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes
Abstract
Objective: The objective of the study was to assess the prevalence and determinants of elevated apolipoprotein B (apoB) and dense low-density lipoprotein (LDL) in United States youth with type 1 or type 2 diabetes.
Methods: We conducted cross-sectional analyses of apoB concentrations, LDL density, and prevalence of elevated apoB levels and dense LDL from the SEARCH for Diabetes in Youth study, a six-center U.S.-based study of youth with diabetes onset younger than 20 years of age (2657 with type 1 and 345 with type 2).
Results: Among youth with type 1 diabetes, 11% had elevated apoB (>or=100 mg/dl, 1.95 mm/liter), 8% had dense LDL (relative flotation rate<or=0.237), and 12% had elevated LDL-cholesterol (>or=130 mg/dl, 3.36 mm/liter). In contrast, among youth with type 2 diabetes, 36% had elevated apoB, 36% had dense LDL, but only 23% had elevated LDL-cholesterol. Dense LDL and apoB each increased with hemoglobin A1c in both types. Among type 1 diabetics in poor glycemic control (hemoglobin A1c>or=9.5%), 28% had elevated apoB, and 18% had dense LDL, whereas 72% of poorly controlled type 2 diabetics had elevated apoB and 62% had dense LDL.
Conclusions: In youth with type 1 diabetes, elevated apoB and dense LDL were not highly prevalent, whereas elevated apoB and dense LDL were common lipoprotein abnormalities in youth with type 2 diabetes. The prevalence of these risk factors substantially increased with poor glycemic control in both groups, stressing the importance of achieving and maintaining an optimal glucose control.
Figures



Similar articles
-
Serum lipids and glucose control: the SEARCH for Diabetes in Youth study.Arch Pediatr Adolesc Med. 2007 Feb;161(2):159-65. doi: 10.1001/archpedi.161.2.159. Arch Pediatr Adolesc Med. 2007. PMID: 17283301
-
Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial.Diabetes Care. 2013 Jun;36(6):1758-64. doi: 10.2337/dc12-2388. Diabetes Care. 2013. PMID: 23704675 Free PMC article. Clinical Trial.
-
Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.Cardiovasc Diabetol. 2017 Oct 2;16(1):123. doi: 10.1186/s12933-017-0606-7. Cardiovasc Diabetol. 2017. PMID: 28969633 Free PMC article.
-
ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels.Korean J Intern Med. 2018 Jan;33(1):138-147. doi: 10.3904/kjim.2017.396. Epub 2017 Dec 28. Korean J Intern Med. 2018. PMID: 29334727 Free PMC article.
-
Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.Am J Cardiol. 2012 Nov 15;110(10):1468-76. doi: 10.1016/j.amjcard.2012.07.007. Epub 2012 Aug 17. Am J Cardiol. 2012. PMID: 22906895 Review.
Cited by
-
Youth-onset type 2 diabetes mellitus: an urgent challenge.Nat Rev Nephrol. 2023 Mar;19(3):168-184. doi: 10.1038/s41581-022-00645-1. Epub 2022 Oct 31. Nat Rev Nephrol. 2023. PMID: 36316388 Free PMC article. Review.
-
Mechanisms and early patterns of dyslipidemia in pediatric type 1 and type 2 diabetes.J Pediatr Endocrinol Metab. 2020 Nov 26;33(11):1399-1408. doi: 10.1515/jpem-2020-0220. J Pediatr Endocrinol Metab. 2020. PMID: 33027052 Free PMC article.
-
Potential Role of Protein Kinase C in the Pathophysiology of Diabetes-Associated Atherosclerosis.Front Pharmacol. 2021 Jul 2;12:716332. doi: 10.3389/fphar.2021.716332. eCollection 2021. Front Pharmacol. 2021. PMID: 34276388 Free PMC article. Review.
-
Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.J Atheroscler Thromb. 2022 Aug 1;29(8):1188-1200. doi: 10.5551/jat.63019. Epub 2021 Aug 30. J Atheroscler Thromb. 2022. PMID: 34456199 Free PMC article.
-
Associations of genetic markers of diabetes mellitus with carotid atherosclerosis: a community-based case-control study.Cardiovasc Diabetol. 2023 Mar 9;22(1):51. doi: 10.1186/s12933-023-01787-7. Cardiovasc Diabetol. 2023. PMID: 36894991 Free PMC article.
References
-
- Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C 2005 Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111:3489–3493 - PubMed
-
- Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR 1987 Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750–755 - PubMed
-
- Laakso M 2001 Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 249:391–393 - PubMed
-
- McGill Jr HC, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP 2000 Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 20:1998–2004 - PubMed
-
- Järvisalo MJ, Putto-Laurila A, Jartti L, Lehtimäki T, Solakivi T, Rönnemaa T, Raitakari OT 2002 Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 51:493–498 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- M01RR00037/RR/NCRR NIH HHS/United States
- U01 DP000247/DP/NCCDPHP CDC HHS/United States
- M01 RR000069/RR/NCRR NIH HHS/United States
- M01 RR01070/RR/NCRR NIH HHS/United States
- M01 RR000037/RR/NCRR NIH HHS/United States
- U01 DP000244/DP/NCCDPHP CDC HHS/United States
- M01 RR001271/RR/NCRR NIH HHS/United States
- M01 RR08084/RR/NCRR NIH HHS/United States
- M01 RR00069/RR/NCRR NIH HHS/United States
- M01 RR001070/RR/NCRR NIH HHS/United States
- U01 DP000250/DP/NCCDPHP CDC HHS/United States
- M01RR001271/RR/NCRR NIH HHS/United States
- U01 DP000245/DP/NCCDPHP CDC HHS/United States
- DP-05-069/DP/NCCDPHP CDC HHS/United States
- M01 RR008084/RR/NCRR NIH HHS/United States
- U01 DP000248/DP/NCCDPHP CDC HHS/United States
- U01 DP000254/DP/NCCDPHP CDC HHS/United States
- PA00097/PHS HHS/United States
- U01 DP000246/DP/NCCDPHP CDC HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous